Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

New England Journal of Medicine

Volumn 349, Issue 5, 2003, Pages 446-456

  Teng, Ming ^a   Wolf, Myles ^b   Lowrie, Edmund ^a   Ofsthun, Norma ^a   Lazarus, J Michael ^a   Thadhani, Ravi ^b  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; PARICALCITOL; PHOSPHORUS; VITAMIN D; ERGOCALCIFEROL; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SURVIVAL; VASCULAR DISEASE; BLOOD; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; COMPARATIVE STUDY; FOLLOW UP; HYPERPARATHYROIDISM; MIDDLE AGED; RENAL OSTEODYSTROPHY; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CALCITRIOL; CALCIUM; COHORT STUDIES; ERGOCALCIFEROLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0042343804     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa022536     Document Type: Article

References (41)

1. Kenal Data System. USRDS 2000 annual data report. Bethesda, Md.: National Institute of Diabetes and Digestive and Kidney Diseases, June 2000.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:Suppl 3:S112, 8119.
3. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription on patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med 1981;305:1176-81.
4. Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993;329:1001-6.
5. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458-82.
6. Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000;20:345-9.
7. Lowrie EG, Teng M, Lacson E, Lew N, Lazarus JM, Owen WF. Association between prevalent care process measures and facility-specific mortality rates. Kidney Int 2001;60: 1917-29.
8. Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 2001;60: 472-9.
9. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342: 1478-83.
10. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
11. Moe SM, O'Neill KD, Duan D, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002;61:638-47.
12. Qunibi WY, Nolan CA, Ayus JC. Cardiovascular calcification in patients with endstage renal disease: a century-old phenomenon. Kidney Int Suppl 2002;82:73-80.
13. Llach F, Yudd M. Pathogenic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure. Am J Kidney Dis 1998;32:Suppl 2:S3-S12.
14. Ifudu O. Care of patients undergoing hemodialysis. N Engl J Med 1998;339:1054-62.
15. Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990;38:931-6.
16. Mallick NP, Berlyne GM. Arterial calcification after vitamin-D therapy in hyperphosphatemic renal failure. Lancet 1968;2:1316-20.
17. Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001;38:Suppl 5:S51-S56.
18. Llach F, Yudd M. Paricalcitol in dialysis patients wtih calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001; 38:Suppl 5:S45-S50.
19. Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002;106:100-5.
20. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8.
21. Martin KJ, Gonzalez EA, Gellens ME, Hamm LL, Abboud H, Lindberg J. Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2. Am J Kidney Dis 1998;32:Suppl 2:S61-S66.
22. Department of Health and Human Services. The international classification of diseases, 9th rev., clinical modification: ICD-9-CM. Washington, D.C.: Government Printing Office, 1980. (DHHS publication no. (PHS) 80-1260.)
23. Couttenye MM, D'Haese PC, Van Hoof VO, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996;11: 1065-72.
24. Ritz E, Schomig M, Bommer J. Osteodystrophy in the millennium. Kidney Int Suppl 1999;73:S94-S98.
25. Goodman WG, Ramirez JA, Belin TR, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994;46:1160-6.
26. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999;33:287-93.
27. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000;36:1115-21.
28. Kuizon BD, Goodman WG, Juppner H, et al. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 1998;53:205-11.
29. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:607-17.
30. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92.
31. Gupta A, Kallenbach LR, Zasuwa G, Divine GW. Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol 2000;11:330-4.
32. Vincenti F, Hattner R, Amend WJ Jr, Feduska NJ, Duca RM, Salvatierra O Jr. Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis. JAMA 1981;245:930-3.
33. Finch JL, Brown AJ, Slatopolsky E. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 1999;10:980-5.
34. Martin KJ, Gonzalez EA. Vitamin D analogues for the management of secondary hyperparathyroidism. Am J Kidney Dis 2001; 38:Suppl 5:S34-S40.
35. Brown AJ, Finch J, Takahashi F, Slatopolsky E. Calcemic activity of 19-nor-1,25 (OH) (2)D(2) decreases with duration of treatment. J Am Soc Nephrol 2000;11:2088-94.
36. Brown AJ. Therapeutic uses of vitamin D analogues. Am J Kidney Dis 2001;38:Suppl 5:S3-S19.
37. Peleg S, Sastry M, Collins ED, Bishop JE, Norman AW. Distinct conformational changes induced by 20-epi analogues of 1 alpha, 25-dihydroxyvitamin D3 are associated with enhanced activation of the vitamin D receptor. J Biol Chem 1995;270:10551-8.
38. Liu YY, Collins ED, Norman AW, Peleg S. Differential interaction of 1 alpha,25-dihydroxyvitamin D3 analogues and their 20-epi homologues with the vitamin D receptor. J Biol Chem 1997;272:3336-45.
39. Zager RA. Calcitriol directly sensitizes renal tubular cells to ATP-depletion- and iron-mediated attack. Am J Pathol 1999;154: 1899-909.
40. Sjoden G, Smith C, Lindgren U, DeLuca HF. 1 Alpha-hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat. Proc Soc Exp Biol Med 1985;178:432-6.
41. Assaf AR, Lapane KL, McKenney JL, Carleton RA. Possible influence of the prospective payment system on the assignment of discharge diagnoses for coronary heart disease. N Engl J Med 1993;329:931-5.